David Mauro
Chief Tech/Sci/R&D Officer presso RECURSION PHARMACEUTICALS, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Attualmente, David J. Mauro ricopre la posizione di responsabile medico per Prelude Therapeutics, Inc. Il dott. Mauro ha precedentemente occupato la posizione di direttore medico e vicepresidente esecutivo presso Advaxis, Inc. e di direttore medico per Checkmate Pharmaceuticals, Inc. Il dott. Mauro ha conseguito una laurea presso la Cornell University e un dottorato presso la Temple University School of Medicine.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
09/02/2024 | 244 629 ( 0.12% ) | 2 M $ | 31/03/2024 |
Posizioni attive di David Mauro
Società | Posizione | Inizio |
---|---|---|
RECURSION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2023 |
Precedenti posizioni note di David Mauro
Società | Posizione | Fine |
---|---|---|
CODIAK BIOSCIENCES | Chief Tech/Sci/R&D Officer | 07/04/2023 |
CHECKMATE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 15/10/2019 |
AYALA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2016 |
MERCK & CO., INC. | Director/Board Member | 01/01/2014 |
BRISTOL-MYERS SQUIBB COMPANY | Director/Board Member | - |
Formazione di David Mauro
Cornell University | Undergraduate Degree |
Temple University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
MERCK & CO., INC. | Health Technology |
RECURSION PHARMACEUTICALS, INC. | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
Aziende private | 3 |
---|---|
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Codiak BioSciences, Inc.
Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- David Mauro